FDA Peptide Tracker

PT-141: live FDA regulatory status

Libido arousal peptide · Sexual health

The two signals

Plain-English verdict: amber.

Regulatory status: Restricted.

These two never collapse into one. Removal from a list is not the same as legal-to-compound, and neither is the same as available.

Availability at Peptós.LIFE

Join waitlist

What PT-141 is

An FDA-approved peptide (as Vyleesi) that raises sexual desire by acting on the brain's arousal pathways, not blood flow.

Short version: the one genuinely FDA-approved desire-side peptide, but only as the branded drug Vyleesi, and only for premenopausal women with HSDD. We don't offer it. This page is the honest education so you can take it to a clinician.

PT-141 works through the brain's arousal pathways, not the plumbing, which is why it reaches people the usual ED options don't. It's the rare desire-side molecule with a real FDA approval behind it, as Vyleesi, for premenopausal women with HSDD. We don't carry it, so instead of over-promising we lay out the honest picture here and send you into a clinician conversation informed.

Why it sits in this category

PT-141 is tracked under Sexual health. Its regulatory status is Restricted — a separate signal from whether you can actually get it today. We never collapse the two.

We don't offer PT-141. It's FDA-approved only as the branded drug Vyleesi (bremelanotide), and only for premenopausal women with acquired, generalized HSDD, a real, legitimate option, just not one in our catalog. Compounded 'PT-141' is a separate, non-FDA-approved route. We educate here and route you to the Knowledge Base; we make no availability promise and show no price.

A melanocortin (MC3R/MC4R) receptor agonist, bremelanotide, acting on central arousal pathways in the brain rather than on blood flow.

What it does — and what it does not do

What it does: Has genuine FDA-approved evidence for one specific use, raising sexual desire in premenopausal women with acquired, generalized HSDD, by working centrally rather than on blood flow.

What it does not do: It is not approved for men or for postmenopausal women (those uses are off-label), it is not a blood-flow 'ED pill,' and it is not something we offer. Branded Vyleesi and compounded bremelanotide are different regulatory things.

What would have to change

Next milestone on the regulatory path: Bulks rulemaking (projected) — 2026–2027. A favorable advisory (PCAC) vote is a recommendation that leads to rulemaking — not FDA approval, not authorization to compound, and not availability.

Evidence grade

Grade A — randomized phase-3 trials (RECONNECT) behind the approved product, bremelanotide / Vyleesi. See our grading methodology for what each grade means.

What we still don't know: Formal efficacy and approval in men aren't established; long-horizon repeated-use effects aren't well characterized. Response and tolerability vary, with nausea and transient blood-pressure changes reported.

Regulatory timeline

PCAC is advisory: its Jul 2026 recommendation leads to rulemaking, not instant availability. A favorable advisory vote is a recommendation, not FDA approval or authorization to compound. Realistic earliest legitimate access is late 2026 into 2027. Reclassification is not the same as FDA approval. Compounded medications are not evaluated or approved by the FDA for safety, efficacy, or quality, where that applies, we say so, plainly.

Primary source: FDA source record

See the full status board or this molecule's knowledge-base monograph.

Last updated July 26, 2026 · Peptós.LIFE · Not medical advice.